FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111784654> ?p ?o ?g. }

• W2111784654 endingPage "3101" @default.
• W2111784654 startingPage "3095" @default.
• W2111784654 abstract "Article16 June 2003free access Expression of truncated PrP targeted to Purkinje cells of PrP knockout mice causes Purkinje cell death and ataxia Eckhard Flechsig Eckhard Flechsig Institut für Molekularbiologie, Universität Zürich, CH-8057 Zürich, Switzerland MRC Prion Unit, Department of Neurodegenerative Disease, Institute of Neurology, Queen Square, London, WC1N 3BG UK Present address: Institut für Viologie und Immunbiologie, Universität Würzburg, D-97078 Würzburg, Germany Search for more papers by this author Ivan Hegyi Ivan Hegyi Institut für Neuropathologie, Universität Zürich, CH-8091 Zürich, Switzerland Search for more papers by this author Rainer Leimeroth Rainer Leimeroth Institut für Molekularbiologie, Universität Zürich, CH-8057 Zürich, Switzerland Present address: Institut für Zellbiologie, ETH-Zürich, Hönggerberg, CH-8093 Zürich, Switzerland Search for more papers by this author Armando Zuniga Armando Zuniga Institut für Molekularbiologie, Universität Zürich, CH-8057 Zürich, Switzerland Search for more papers by this author Daniela Rossi Daniela Rossi Institut für Molekularbiologie, Universität Zürich, CH-8057 Zürich, Switzerland MRC Prion Unit, Department of Neurodegenerative Disease, Institute of Neurology, Queen Square, London, WC1N 3BG UK Present address: Department of Pharmacological Sciences, Center for Excellence on Neurodegenerative Diseases, University of Milan, 20133 Milan, Italy Search for more papers by this author Antonio Cozzio Antonio Cozzio Institut für Molekularbiologie, Universität Zürich, CH-8057 Zürich, Switzerland Present address: Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305 USA Search for more papers by this author Petra Schwarz Petra Schwarz Institut für Neuropathologie, Universität Zürich, CH-8091 Zürich, Switzerland Search for more papers by this author Thomas Rülicke Thomas Rülicke Biologisches Zentrallabor, Institut für Labortierkunde, Universität Zürich, CH-8091 Zürich, Switzerland Search for more papers by this author Jürgen Götz Jürgen Götz Institut für Molekularbiologie, Universität Zürich, CH-8057 Zürich, Switzerland Present address: Psychiatrische Universitätsklinik, CH-8029 Zürich, Switzerland Search for more papers by this author Adriano Aguzzi Adriano Aguzzi Institut für Neuropathologie, Universität Zürich, CH-8091 Zürich, Switzerland Search for more papers by this author Charles Weissmann Corresponding Author Charles Weissmann Institut für Molekularbiologie, Universität Zürich, CH-8057 Zürich, Switzerland MRC Prion Unit, Department of Neurodegenerative Disease, Institute of Neurology, Queen Square, London, WC1N 3BG UK Search for more papers by this author Eckhard Flechsig Eckhard Flechsig Institut für Molekularbiologie, Universität Zürich, CH-8057 Zürich, Switzerland MRC Prion Unit, Department of Neurodegenerative Disease, Institute of Neurology, Queen Square, London, WC1N 3BG UK Present address: Institut für Viologie und Immunbiologie, Universität Würzburg, D-97078 Würzburg, Germany Search for more papers by this author Ivan Hegyi Ivan Hegyi Institut für Neuropathologie, Universität Zürich, CH-8091 Zürich, Switzerland Search for more papers by this author Rainer Leimeroth Rainer Leimeroth Institut für Molekularbiologie, Universität Zürich, CH-8057 Zürich, Switzerland Present address: Institut für Zellbiologie, ETH-Zürich, Hönggerberg, CH-8093 Zürich, Switzerland Search for more papers by this author Armando Zuniga Armando Zuniga Institut für Molekularbiologie, Universität Zürich, CH-8057 Zürich, Switzerland Search for more papers by this author Daniela Rossi Daniela Rossi Institut für Molekularbiologie, Universität Zürich, CH-8057 Zürich, Switzerland MRC Prion Unit, Department of Neurodegenerative Disease, Institute of Neurology, Queen Square, London, WC1N 3BG UK Present address: Department of Pharmacological Sciences, Center for Excellence on Neurodegenerative Diseases, University of Milan, 20133 Milan, Italy Search for more papers by this author Antonio Cozzio Antonio Cozzio Institut für Molekularbiologie, Universität Zürich, CH-8057 Zürich, Switzerland Present address: Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305 USA Search for more papers by this author Petra Schwarz Petra Schwarz Institut für Neuropathologie, Universität Zürich, CH-8091 Zürich, Switzerland Search for more papers by this author Thomas Rülicke Thomas Rülicke Biologisches Zentrallabor, Institut für Labortierkunde, Universität Zürich, CH-8091 Zürich, Switzerland Search for more papers by this author Jürgen Götz Jürgen Götz Institut für Molekularbiologie, Universität Zürich, CH-8057 Zürich, Switzerland Present address: Psychiatrische Universitätsklinik, CH-8029 Zürich, Switzerland Search for more papers by this author Adriano Aguzzi Adriano Aguzzi Institut für Neuropathologie, Universität Zürich, CH-8091 Zürich, Switzerland Search for more papers by this author Charles Weissmann Corresponding Author Charles Weissmann Institut für Molekularbiologie, Universität Zürich, CH-8057 Zürich, Switzerland MRC Prion Unit, Department of Neurodegenerative Disease, Institute of Neurology, Queen Square, London, WC1N 3BG UK Search for more papers by this author Author Information Eckhard Flechsig1,2,3, Ivan Hegyi4, Rainer Leimeroth1,5, Armando Zuniga1, Daniela Rossi1,2,6, Antonio Cozzio1,7, Petra Schwarz4, Thomas Rülicke8, Jürgen Götz1,9, Adriano Aguzzi4 and Charles Weissmann 1,2 1Institut für Molekularbiologie, Universität Zürich, CH-8057 Zürich, Switzerland 2MRC Prion Unit, Department of Neurodegenerative Disease, Institute of Neurology, Queen Square, London, WC1N 3BG UK 3Present address: Institut für Viologie und Immunbiologie, Universität Würzburg, D-97078 Würzburg, Germany 4Institut für Neuropathologie, Universität Zürich, CH-8091 Zürich, Switzerland 5Present address: Institut für Zellbiologie, ETH-Zürich, Hönggerberg, CH-8093 Zürich, Switzerland 6Present address: Department of Pharmacological Sciences, Center for Excellence on Neurodegenerative Diseases, University of Milan, 20133 Milan, Italy 7Present address: Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305 USA 8Biologisches Zentrallabor, Institut für Labortierkunde, Universität Zürich, CH-8091 Zürich, Switzerland 9Present address: Psychiatrische Universitätsklinik, CH-8029 Zürich, Switzerland ‡E.Flechsig, I.Hegyi and R.Leimeroth contributed equally to this work *Corresponding author. E-mail: [email protected] The EMBO Journal (2003)22:3095-3101https://doi.org/10.1093/emboj/cdg285 PDFDownload PDF of article text and main figures. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info PrP knockout mice with disruption of only the PrP-encoding region (Zürich I-type) remain healthy, whereas mice with deletions extending upstream of the PrP-encoding exon (Nagasaki-type) suffer Purkinje cell loss and ataxia, associated with ectopic expression of Doppel in brain, particularly in Purkinje cells. The phenotype is abrogated by co-expression of full-length PrP. Doppel is 25% similar to PrP, has the same globular fold, but lacks the flexible N-terminal tail. We now show that in Zürich I-type PrP-null mice, expression of N-terminally truncated PrP targeted to Purkinje cells also leads to Purkinje cell loss and ataxia, which are reversed by PrP. Doppel and truncated PrP probably cause Purkinje cell degeneration by the same mechanism. Introduction The prion protein (PrP) plays a central role in the pathogenesis of transmissible spongiform encephalopathies (TSEs) such as Creutzfeldt–Jakob disease (CJD) or bovine spongiform encephalopathy (BSE) (Prusiner, 1996; Weissmann et al., 1996; Prusiner et al., 1998; Weissmann, 1999). Mice devoid of PrP are resistant to scrapie and fail to propagate prions (Büeler et al., 1993; Manson et al., 1994b; Sailer et al., 1994; Sakaguchi et al., 1995); introduction of PrP-encoding transgenes restores susceptibility to the disease (Fischer et al., 1996). The cellular form of the prion protein, PrPC, is encoded by a single-copy gene (Basler et al., 1986). It is attached by a glycosylphosphatidyl inositol (GPI) anchor to the outer cell surface and is found mainly in the brain, at neuronal synapses (Sales et al., 1998). PrPC comprises a globular domain consisting of three α-helices, one short antiparallel β-sheet and a single disulfide bond (Riek et al., 1996). The N-terminal half of the molecule is highly flexible (Donne et al., 1997; Riek et al., 1997). Several PrP knockout mouse lines have been generated, differing in the design of the gene disruption (reviewed in Weissmann and Aguzzi, 1999). Two lines in which only the PrP-coding sequence was disrupted (Büeler et al., 1992; Manson et al., 1994a), to be referred to as ‘Zürich I-type’ mice, developed normally and remained healthy, showing only minor electrophysiological deficits (Collinge et al., 1994; Colling et al., 1996) and altered circadian rhythm (Tobler et al., 1996). However, three other lines with more extensive gene deletions, ‘Nagasaki-type’ PrP knockout mice, developed Purkinje cell loss followed by ataxia (Sakaguchi et al., 1996; Moore et al., 1999; Rossi et al., 2001). Because the ataxic phenotype could be rescued by a PrP-encoding transgene, it originally was concluded that the phenotype was due to the absence of PrP (Sakaguchi et al., 1996; Nishida et al., 1999), although the conclusion was incompatible with the earlier reports (Weissmann, 1996). It was found later that the ataxic phenotype of all three Nagasaki-type lines is associated with ectopic expression of the PrP-like protein Doppel (Dpl) in brain (Moore et al., 1999; Li et al., 2000a; Rossi et al., 2001). Dpl is an N-glycosylated, GPI-anchored protein (Lu et al., 2000; Silverman et al., 2000), normally expressed in a variety of tissues but not in postnatal brain (Moore et al., 1999; Li et al., 2000b). Its physiological function is still unknown, but its absence causes male sterility in mice (Behrens et al., 2002). Dpl and PrP show ∼25% sequence similarity (Moore et al., 1999), and both comprise three α-helices and one antiparallel β-sheet in a similar fold, with only minor differences (Lu et al., 2000; Silverman et al., 2000; Mo et al., 2001). Dpl is encoded by Prnd, located 16 kb downstream of the Prnp gene (Moore et al., 1999). The loss of the splice acceptor site of the PrP-encoding Prnp exon 3, a consequence of the PrP gene deletion strategy in Nagasaki-type mice, causes formation of chimeric transcripts containing the first two non-coding exons of the Prnp locus linked to the Dpl-encoding Prnd exon. This places Dpl expression under the control of the Prnp promoter (Moore et al., 1999; Li et al., 2000a). The time to onset of disease is inversely correlated with the expression level of Dpl in the brain and is rescued by co-expression of PrPC (Rossi et al., 2001). Thus, ectopic expression of Dpl in the absence of PrP, rather than the absence of PrPC in itself, causes Purkinje cell loss in Nagasaki-type PrP knockout mice. Moore et al. (2001) reported that transgenic Prnpo/o mice expressing Dpl ubiquitously in brain developed severe ataxia associated with loss of both granule and Purkinje cells. The age of onset was inversely proportional to the level of Dpl expression, and 1-month-old mice were already affected (Moore et al., 2001). Introduction of a hamster PrP-encoding transgene resulted in complete abrogation of the cerebellar syndrome in mice expressing moderate levels, and partial abrogation in animals expressing high levels of Dpl. Both unaltered incubation times and pathology in brain tissue expressing PrP and Dpl upon challenge with different prion strains sustain the conclusion (Behrens et al., 2001) that Dpl is unlikely to be involved in prion pathogeneses (Moore et al., 2001; Tuzi et al., 2002). We reported earlier that expression in PrP knockout mice of PrP lacking the flexible N-terminal tail (PrPΔ32–121 or PrPΔ32–134) gives rise to a dose-dependent phenotype comprising ataxia and loss of cerebellar granule cells, which is abrogated by co-expression of wild-type PrP (Shmerling et al., 1998). Shmerling et al. proposed that the binding of PrP to a putative ligand elicits a signal necessary for cell survival and that a functional homologue of PrP supplies this function in its absence. Expression of truncated PrP was postulated to interfere with signalling by displacing the functional homologue from the ligand without eliciting the survival signal of PrP. PrP, in turn, because of its higher affinity for the ligand, would displace its truncated counterpart and restore the signal (Shmerling et al., 1998). Because the overall structure of Dpl is remarkably similar to that of the globular domain of PrP lacking the flexible N-terminus, the mechanism of pathogenesis might be the same in both ataxic syndromes (Moore et al., 1999; Weissmann and Aguzzi, 1999). Why, however, should truncated PrP cause degeneration of granule cells while Dpl entails Purkinje cell loss if the mechanism is the same? Perhaps it is because the ‘half-genomic’ PrP vector used to express the truncated PrP is inactive in Purkinje cells, but very active in granule cells (Fischer et al., 1996; Chiesa et al., 1998), whilst Dpl, under the control of the intact PrP promoter, is strongly upregulated in Purkinje cells and much less so in granule cells (Li et al., 2000a). To test this hypothesis, we targeted truncated PrP specifically to Purkinje cells of Zürich I-type PrP knockout mice to determine whether the resulting phenotype would be the same as that of Nagasaki-type PrP knockout mice with ectopic expression of Dpl, namely age-dependent Purkinje cell loss followed by ataxia, suppressible by a single wild-type PrP allele. Results Purkinje cell loss and ataxia in mice expressing the truncated PrP under the control of the L7 promoter We expressed PrP devoid of residues 32–134 (PrPΔ32–134) under the control of the Purkinje cell-specific L7 promoter (Oberdick et al., 1990) in Zürich I Prnpo/o mice (Büeler et al., 1992). Three transgenic lines, TgF32, TgF37 and TgF13, were generated and analysed (Table I; Figure 1). Truncated PrP was detectable only in Purkinje cells, as judged by immunohistochemistry for PrP (Figure 2). Within the Purkinje cells, truncated PrP is highly expressed in cell bodies, axons and dendrites, as shown in 3-week-old TgF13 mice (Figures 2 and 3). Mice hemizygous for the transgene cluster on a Prnpo/o background showed the first signs of behavioural abnormalities, such as reduced exploratory activities and mild trembling gait, at ∼2 months. Mice displaying these abnormalities were scored as affected (ataxic syndrome) (Figure 1). The ataxic syndrome was present in 50% of analysed mice by ∼9–11 weeks, depending on the line (Table I). Ataxia and trembling gait increased over time, and footprint analysis revealed a similar pattern to that described for the Nagasaki-type Zürich II PrP knockout mice (Rossi et al., 2001). After ∼1 year, the general poor condition of the mice precluded further maintenance. Figure 1.Age at onset of ataxic syndrome in mice expressing the truncated PrP (PrPΔ32–134) under the control of the Purkinje cell-specific L7 promoter. Hemizygous mice (L7-ΔPrP/−) of the lines TgF13 (n = 10), TgF32 (n = 14) and Tg37 (n = 21) were assessed at 2-week intervals for behavioural abnormalities, such as reduced exploratory activities, trembling gait and ataxia. Mice displaying these abnormalities were scored as affected. This syndrome was present in 50% of mice analysed by ∼9 and 11 weeks of age, depending on the line (Table I). Introduction of a single wild-type allele (Prnp+) or a transgenic cluster (Tga20) into the TgF13 line abrogated the ataxic phenotype in F1 offspring (TgF13,Prnp+/o; n = 8) and (TgF13,Tga20/−,Prnpo/o; n = 11), respectively. Download figure Download PowerPoint Figure 2.Time course of Purkinje cell degeneration in Zürich I Prnpo/o mice expressing truncated PrP (PrPΔ32–134) under the control of the Purkinje cell-specific L7 promoter. Immunostaining for calbindin (top row), PrP (middle row) and GFAP (lower row) of sections through cerebella of L7-ΔPrP mice (TgF13) are shown. Sections were immunostained for PrP using R340 and TSA amplification as described in Materials and methods. GFAP and calbindin were visualized as described in Materials and methods. Three-week-old mice show normal cerebellar structure with weak gliosis. Truncated PrP is highly expressed in Purkinje cell bodies, axons and dendrites, but not in granule cells. After onset of ataxia, 14-week-old mice present with Purkinje cell loss and moderate gliosis in the molecular layer. At 25 weeks, mice show an extended Purkinje cell loss associated with moderate gliosis. In 49-week-old mice, there is an almost complete Purkinje cell loss, shrinkage of the molecular layer, decrease of granular cells and intense gliosis; a single, remaining Purkinje cell is PrP positive. Age-matched controls (Prnpo/o, Prnpo/+) show an intact Purkinje cell layer and no gliosis. Download figure Download PowerPoint Figure 3.Immunostaining for PrP in Purkinje cells of wild-type, PrP knockout and L7-ΔPrP transgenic mice. Cerebellar sections were immunostained for PrP using R340 and TSA amplification as described in Materials and methods. The truncated PrP is strongly overexpressed in Purkinje cell bodies, axons and dendrites of 3-week-old TgF13 mice (TgF13,Prnpo/o) in comparison with a faint staining in wild-type controls (Prnp+/+). No background staining was found in the same area of PrP knockout mice (Prnpo/o) processed in parallel with all sections shown. Introduction of a single wild-type Prnp+ allele in transgenic mice completely abrogated the ataxic phenotype. L7-ΔPrP transgene expression is not decreased in 3-week-old mice (TgF13/−,Prnpo/+) or older mice (data not shown). It is striking that the pathogenic effect of the truncated PrP at levels several times higher than PrP levels in wild-type mice is completely abolished by a single Prnp+ allele, suggesting a highly specific effect of wild-type PrP in counteracting the L7-ΔPrP-induced cell degeneration. Download figure Download PowerPoint Table 1. Zürich I PrP knockout mouse lines expressing truncated PrP (PrPΔ32–134) under the control of the Purkinje cell-specific L7 promoter Name of the linea Genotype Transgene copy numberb Age at onset of ataxia (weeks)c Mice analysed TgF32 Prnpo/o, Tg L7-ΔPrP/– 130 9 14 TgF37 Prnpo/o, Tg L7-ΔPrP/− 120 9 21 TgF13 Prnpo/o, Tg L7-ΔPrP/− 60 11 10 TgF13/Prnpo/+ Prnpo/+, Tg L7-ΔPrP/− n.d. >49 8 TgF13/Tga20 Prnpo/o, Tg L7-ΔPrP/, Tga20/− n.d. >70 11 a The full designations of the lines are Prnp-Tg(PrPΔ134)332 Zbz for TgF32, Prnp-Tg(PrPΔ134)337 Zbz for TgF37, and B6D2F1-Tg(PrPΔ134)13 for TgF13. b Transgenic copy numbers were estimated relative to standards by quantitative PCR using primers SIG and Mut217 (Shmerling et al., 1998). As standards, mouse DNA containing 30 and 40 copies of the transgene cluster PrPΔ32–80 obtained from D11 and D12 mice were used, respectively (Fischer et al., 1996). Because TgF13 mice showed the highest expression level of Purkinje cell-specific PrP and the most uniform labelling, all complementation and time course experiments were carried out with this line. c Average age of mice when the phenotype was present in 50% of the mice analysed. Earliest onset and 100% morbidity were different for each line, as shown in Figure 1. n.d., not done. The TgF13 line was selected for further analysis, because it was the earliest to reach 100% morbidity (Figure 1). Moreover, TgF13 mice had the highest level of Purkinje cell-specific expression of the truncated PrP, as judged by immunohistochemistry for PrP (data not shown), and virtually all Purkinje cells were uniformly labelled by immunostaining for PrP (Figures 2 and 3). We analysed cerebellar sections of TgF13 mice for histopathological changes before and after onset of symptoms (Figure 2). At 3 weeks of age, there was marginal Purkinje cell loss associated with slight gliosis in the molecular layer, while the granular cell layer was normal. At 14 weeks, when behavioural abnormalities were present in ∼80% of the mice (Figure 1), there was severe focal and moderate overall Purkinje cell loss accompanied by astrogliosis in the molecular layer (Figure 2). Purkinje cell bodies varied focally in shape and size, and some were negative for calbindin, a specific Purkinje cell marker. Degeneration progressed over the following months with severe Purkinje cell loss and gliosis in the molecular layer followed by shrinkage of the molecular layer and granule cell loss. At 25 weeks, 3 months after onset of symptoms, the number of Purkinje cell bodies and their dendrites in the molecular layer was dramatically reduced (Figures 2 and 4A) and astrogliosis was evident in both molecular and granule cell layers. At 49 weeks, Purkinje cells had virtually disappeared; the very few remaining Purkinje cells still expressed the (truncated) PrP both in soma and dendrites (Figure 2). Shrinkage of the molecular layer was striking and gliosis was prominent. There was neither Purkinje cell loss nor glial fibrillary acidic protein (GFAP) immunoreactivity in age-matched Prnpo/o and Prnpo/+ mice (Figure 2), indicating that the age-dependent Purkinje cell loss in the transgenic mice was due to L7-specific expression of truncated PrP, rather than to the absence of PrP. The phenotype of the L7-ΔPrP mice was thus similar to that of the three Nagasaki-type PrP knockout lines exhibiting upregulation of Dpl (Sakaguchi et al., 1996; Moore et al., 1999; Rossi et al., 2001). In Zürich II PrP knockout mice, which are of the Nagasaki-type, there was an average Purkinje cell loss of 40% at 30 weeks, and at 40 weeks 50% of the mice were ataxic (Rossi et al., 2001). As in the case of L7-ΔPrP mice, Dpl-induced Purkinje cell loss progressed over several months and exceeded 80% after 63 weeks (Rossi et al., 2001). Purkinje cell loss was also accompanied by cerebellar astrogliosis (Atarashi et al., 2001; Rossi et al., 2001). Figure 4.Purkinje cell degeneration in L7-ΔPrP transgenic mice is mitigated by co-expression of PrP. Cerebellar sections were immunostained for calbindin, a marker for Purkinje cells. Prnpo/o and wild-type (Prnp+/+) controls show normal Purkinje cell layers at 40 and 43 weeks, respectively. (A) L7-ΔPrP mice (TgF13/−,Prnpo/o) at 25 weeks presented with severe loss of Purkinje cell dendrites and cell bodies, associated with a reduction of the molecular layer. In the presence of a wild-type allele (TgF13/−,Prnpo/+), Purkinje cell loss was completely abrogated at 25 weeks and strongly mitigated at 35 weeks. (B) Introduction of the Tga20 transgene cluster into L7-ΔPrP mice (TgF13/−,Tga20/−,Prnpo/o) resulted in PrP expression in brain, except in the Purkinje cells; in these mice, Purkinje cell loss was practically abrogated at 20 weeks and mitigated at 85 weeks of age. There was also a slight Purkinje cell loss in the age-matched controls (Tga20/−,Prnpo/o). Download figure Download PowerPoint Abrogation of the pathogenic effect of truncated PrP by a Prnp wild-type allele We next examined whether co-expression of PrP could rescue the phenotype as described for the Nagasaki-type mice (Nishida et al., 1999; Rossi et al., 2001). TgF13 mice (expressing L7-ΔPrP) were crossed with C57BL/6 mice, and the resulting transgenic TgF13/−,Prnpo/+ mice were assessed by their home cage behaviour for 1 year. Introduction of the wild-type PrP allele did not downregulate the expression of the truncated PrP in the Purkinje cells (Figure 3). As shown in Figure 1, all eight transgenic TgF13/−,Prnpo/+ mice analysed remained healthy for >11 months. Cerebella of transgenic TgF13/−,Prnpo/+ mice were analysed for Purkinje cell loss at 25 weeks, 35 weeks and 1 year of age. No obvious reduction in the number of Purkinje cells (Figure 4A) and no astrogliosis (data not shown) were observed at 25 weeks of age, when severe Purkinje cell loss and reduction of the molecular layer were evident in the absence of a wild-type PrP allele. At 35 weeks, there was a slight to moderate loss of Purkinje cells with a few reactive Bergman glia cells, but no astrogliosis in the molecular layer (data not shown). Cerebella of 1-year-old healthy TgF13/−,Prnpo/+ mice showed moderate Purkinje cell loss that was not found in aged-matched Prnpo/+ mice (data not shown). In contrast, Purkinje cells were completely absent and shrinkage of the molecular layer was evident in 1-year-old ataxic transgenic TgF13/−,Prnpo/o mice. There was a moderate loss of granule cells, possibly due to disappearance of their Purkinje cell targets, which was not found in Prnpo/+ controls (data not shown). Thus, a wild-type PrP allele fully abrogated the clinical manifestations elicited by L7-ΔPrP transgene expression, although it did not completely suppress Purkinje cell loss. Similarly, mice carrying one wild-type PrP and one Zürich II PrP allele showed no clinical symptoms after as long as 100 weeks (Rossi et al., 2001). Abrogation of the pathogenic effect of truncated PrP by a Tga20 allele cluster expressing PrP in brain with the exception of Purkinje cells It was suggested earlier that PrP did not have to be expressed in Purkinje cells in order to rescue the Dpl-induced phenotype in Zürich II mice (Rossi et al., 2001) because PrP expressed under the direction of the ‘half-genomic’ PrP promoter (the Tga20 gene cluster) abrogated the clinical phenotype, although this promoter is active in brain in general but not in Purkinje cells (Fischer et al., 1996; Rossi et al., 2001). We bred the Tga20 allele cluster into transgenic TgF13/−,Prnpo/o mice. Of 11 double transgenic mice (TgF13/−,Tga20/−,Prnpo/o) analysed, none developed behavioural abnormalities within 1 year (Figure 1). At 20 weeks, there was complete suppression of Purkinje cell degeneration in the cerebella of those mice (Figure 4B). However, we found moderate Purkinje cell loss in an 85-week-old double-transgenic mouse, as compared with slight Purkinje cell loss, without astrogliosis, in a 78-week-old control mouse hemizygous for the Tga20 allele cluster. We cannot exclude the possibility that levels of PrP undetectable by our immunohistochemical analysis sufficed to ensure Purkinje cell survival. Alternatively, perhaps PrP expressed at the synapses of neighbouring cells can supply the protective effect or can be physically transferred, as shown for PrP in vitro (Liu et al., 2002) and for other GPI-linked proteins in vitro (Anderson et al., 1996) and in vivo (Kooyman et al., 1995). In Purkinje cells of wild-type mice, PrP is found at pre- and postsynaptic spines (Haeberle et al., 2000). In the cerebellum, PrP is also found on other neuronal cells, such as Golgi type II, stellate and basket cells, and to a lesser extent on granule cells (Laine et al., 2001; Liu et al., 2001; Ford et al., 2002). Discussion This project aimed to determine whether expression of N-terminally truncated PrP (PrPΔ32–134) targeted specifically to Purkinje cells of Zürich I PrP knockout mice resulted in the same phenotype observed in three lines of Nagasaki-type PrP knockout mice with upregulation of Dpl in brain, namely ataxia and Purkinje cell degeneration, which was abrogated by PrP. Indeed, transgenic mice overexpressing truncated PrP in Purkinje cells under the control of the L7 promoter developed ataxia and Purkinje cell degeneration similar to that of Nagasaki-type mice, but 8 months earlier than the latter (Rossi et al., 2001). Because onset of ataxia in Nagasaki-type PrP knockout mice is inversely correlated with the expression levels of Dpl in the brain (Rossi et al., 2001), we assume that the earlier onset of the phenotype in our L7-ΔPrP transgenic lines is due to the high expression level of the truncated PrP. Introduction of a wild-type PrP allele into L7-ΔPrP transgenic Prnpo/o mice rescued the phenotype completely: there was no Purkinje cell loss in L7-ΔPrP transgenic Prnpo/+ at 6 months of age and only a slight reduction of Purkinje cells in mice older than 8 months. Similarly, Purkinje cell degeneration caused by ectopic expression of Dpl in a Nagasaki-type line Zürich II was suppressed in the presence of a wild-type Prnp or Tga20 allele for >20 months, and there was also a mild Purkinje cell loss in older mice expressing the Tga20 allele (Rossi et al., 2001). Moreover, Dpl-induced Purkinje cell loss in Nagasaki-type lines is accompanied by astrogliosis (Sakaguchi et al., 1996; Rossi et al., 2001). Astrogliosis was present in the cerebellum, but also in the white matter of the forebrain. Because there was no evidence of neuronal damage other than Purkinje cell degeneration, the reason for activation of glia and microglia in the forebrain of Nagasaki PrP-null mice remains unclear (Atarashi et al., 2001). In the cerebellum, astrogliosis occurred several months before the onset of Purkinje cell degeneration (Atarashi et al., 2001). Likewise, astrogliosis is already apparent in 3-week-old L7-ΔPrP transgenic Prnpo/o mice, when the Purkinje cell layer appears still normal. Astrogliosis is a prominent histopathological feature in Dpl- and L7-ΔPrP-expressing PrP null mice, which is completely absent in the presence of wild-type PrP. Taken together, the phenotype caused by the L7-controlled overexpression of the truncated PrP (PrPΔ32–134) and its rescue by wild-type PrP stro" @default.
• W2111784654 created "2016-06-24" @default.
• W2111784654 creator A5008492560 @default.
• W2111784654 creator A5009127040 @default.
• W2111784654 creator A5022424608 @default.
• W2111784654 creator A5026438561 @default.
• W2111784654 creator A5026533191 @default.
• W2111784654 creator A5040052716 @default.
• W2111784654 creator A5040997783 @default.
• W2111784654 creator A5071586379 @default.
• W2111784654 creator A5072397705 @default.
• W2111784654 creator A5078393905 @default.
• W2111784654 creator A5080808665 @default.
• W2111784654 date "2003-06-16" @default.
• W2111784654 modified "2023-10-16" @default.
• W2111784654 title "Expression of truncated PrP targeted to Purkinje cells of PrP knockout mice causes Purkinje cell death and ataxia" @default.
• W2111784654 cites W1535883711 @default.
• W2111784654 cites W1549404680 @default.
• W2111784654 cites W1563777667 @default.
• W2111784654 cites W1564931773 @default.
• W2111784654 cites W1591693496 @default.
• W2111784654 cites W1594545009 @default.
• W2111784654 cites W1665321266 @default.
• W2111784654 cites W1777433224 @default.
• W2111784654 cites W1974443289 @default.
• W2111784654 cites W1974764248 @default.
• W2111784654 cites W1976863839 @default.
• W2111784654 cites W1977614131 @default.
• W2111784654 cites W1978217169 @default.
• W2111784654 cites W1979695510 @default.
• W2111784654 cites W1981250435 @default.
• W2111784654 cites W1987268193 @default.
• W2111784654 cites W1990496336 @default.
• W2111784654 cites W1992380356 @default.
• W2111784654 cites W1995455102 @default.
• W2111784654 cites W1997781327 @default.
• W2111784654 cites W2005533062 @default.
• W2111784654 cites W2006810449 @default.
• W2111784654 cites W2008004502 @default.
• W2111784654 cites W2012109320 @default.
• W2111784654 cites W2015774470 @default.
• W2111784654 cites W2018739152 @default.
• W2111784654 cites W2019428711 @default.
• W2111784654 cites W2027357150 @default.
• W2111784654 cites W2027907160 @default.
• W2111784654 cites W2033069663 @default.
• W2111784654 cites W2041442366 @default.
• W2111784654 cites W2042978244 @default.
• W2111784654 cites W2043601483 @default.
• W2111784654 cites W2043727620 @default.
• W2111784654 cites W2051968416 @default.
• W2111784654 cites W2054532906 @default.
• W2111784654 cites W2058659733 @default.
• W2111784654 cites W2069720350 @default.
• W2111784654 cites W2080514032 @default.
• W2111784654 cites W2086705852 @default.
• W2111784654 cites W2087174680 @default.
• W2111784654 cites W2095221909 @default.
• W2111784654 cites W2108180175 @default.
• W2111784654 cites W2108645326 @default.
• W2111784654 cites W2109401365 @default.
• W2111784654 cites W2128057594 @default.
• W2111784654 cites W2139464576 @default.
• W2111784654 cites W2143795630 @default.
• W2111784654 cites W2147276565 @default.
• W2111784654 cites W2147592113 @default.
• W2111784654 cites W2152958744 @default.
• W2111784654 cites W2289884299 @default.
• W2111784654 cites W2416807128 @default.
• W2111784654 cites W329392657 @default.
• W2111784654 cites W33695110 @default.
• W2111784654 doi "https://doi.org/10.1093/emboj/cdg285" @default.
• W2111784654 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/162137" @default.
• W2111784654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12805223" @default.
• W2111784654 hasPublicationYear "2003" @default.
• W2111784654 type Work @default.
• W2111784654 sameAs 2111784654 @default.
• W2111784654 citedByCount "72" @default.
• W2111784654 countsByYear W21117846542012 @default.
• W2111784654 countsByYear W21117846542013 @default.
• W2111784654 countsByYear W21117846542015 @default.
• W2111784654 countsByYear W21117846542016 @default.
• W2111784654 countsByYear W21117846542017 @default.
• W2111784654 countsByYear W21117846542020 @default.
• W2111784654 countsByYear W21117846542021 @default.
• W2111784654 countsByYear W21117846542022 @default.
• W2111784654 crossrefType "journal-article" @default.
• W2111784654 hasAuthorship W2111784654A5008492560 @default.
• W2111784654 hasAuthorship W2111784654A5009127040 @default.
• W2111784654 hasAuthorship W2111784654A5022424608 @default.
• W2111784654 hasAuthorship W2111784654A5026438561 @default.
• W2111784654 hasAuthorship W2111784654A5026533191 @default.
• W2111784654 hasAuthorship W2111784654A5040052716 @default.
• W2111784654 hasAuthorship W2111784654A5040997783 @default.
• W2111784654 hasAuthorship W2111784654A5071586379 @default.
• W2111784654 hasAuthorship W2111784654A5072397705 @default.
• W2111784654 hasAuthorship W2111784654A5078393905 @default.
• W2111784654 hasAuthorship W2111784654A5080808665 @default.

• next